Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter, parallel, placebo-controlled, phase III study
for evaluation of clinical efficacy and immunogenicity of drug Eritromax® - (rHuEPO Blau
Farmacêutica S/A.) compared to Eprex® (Janssen-Cilag rHuEPO) for the treatment of patients
with secondary anemia to chronic kidney disease (CKD), throughout the correction phase by
assessing the change in hemoglobin levels.